Australia markets open in 9 hours 11 minutes

Instil Bio, Inc. (TIL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
22.33+2.52 (+12.72%)
At close: 04:00PM EST
22.33 0.00 (0.00%)
Pre-market: 08:25AM EST
Full screen
Trade prices are not sourced from all markets
Previous close19.81
Open20.12
Bid0.00 x 900
Ask0.00 x 800
Day's range19.80 - 22.77
52-week range14.42 - 29.49
Volume767,224
Avg. volume379,898
Market cap2.879B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.58
Earnings date15 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est30.00
  • GlobeNewswire

    Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    DALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced poster presentations demonstrating pre-clinical data of the CoStimulatory Antigen Receptor (CoStAR) platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2021), held from November 10-14, 2021. Instil also presen

  • GlobeNewswire

    Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

    Patients enrolled and recruitment ongoing in Phase 2 trial of ITIL-168 in melanoma (DELTA-1)Fast Track Designation granted by FDA for ITIL-168 in metastatic melanomaCoStAR mechanism of action data presented at SITC 2021Successful pre-IND meeting for ITIL-306 DALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or (TIL), therapies for the treatment of patients with cance

  • GlobeNewswire

    Instil Bio to Present at Upcoming Investor Conferences in November

    DALLAS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in two upcoming investor conferences in November: Cowen 5th Annual IO Next SummitMonday, November 15, 2021Session Time: 4:45 PM – 5:05 PM ETLive Session Link: https://wsw.com/admin/link/presenter.aspx?